Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

video

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.
video

“Best Survival Data Yet” With Nelarabine in T-Cell ALL

Kimberly P. Dunsmore, MD, discusses results from the largest trial conducted of young patients with newly diagnosed T-cell acute lymphocytic leukemia, which produced survival...
video

Positive Results With Ivosidenib in IDH1-Mutated AML

Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months...
video

Allogeneic Transplant Plus NK Cells in High-Risk Myeloma

Dr. Shah discusses natural killer cells for myeloma - a cellular therapy that "kills" without causing graft-versus-host disease.
video

Evaluating New Myeloma Agent Combinations in Lenalidomide-Refractory Patients

Dr. Chari reports results from a trial of daratumumab plus carfilzomib-dexamethasone in patients with lenalidomide-refractory disease.

Pulling Back the Curtain: Brian J. Bolwell, MD

Hear more from our interview with Dr. Bolwell, where he shares what he looks for in new recruits and who his dream dinner party guest...

Pulling Back the Curtain: Olatoyosi Odenike, MD

Hear more from our interview with Dr. Odenike, where she describes finding her home in hematology, and offers advice for early-career doctors.

Big Questions, Tough Answers: Norman “Ned” Sharpless, MD

In more from our interview, Dr. Sharpless shares his vision as National Cancer Institute Director and for overcoming the obstacles to advancing research.

Pulling Back the Curtain: Andra James, MD, MPH

Hear more from our interview with Dr. James, where she shares more about the patients who inspired her to pursue hematology and the importance...
video

Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin...

In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.